Section 6: Putting It Together: The Acute Mania Prescribing Algorithm

6.1 First Presentation Versus Known Bipolar: Different Starting Points

The prescribing algorithm branches at the very first question: is this a first manic episode, or a relapse in a patient with established bipolar disorder?

First-episode mania introduces diagnostic uncertainty that changes the clinical approach. The immediate priority is ruling out secondary causes: substance-induced mania (cocaine, amphetamines, synthetic cathinones), medical conditions that mimic mania (hyperthyroidism, CNS tumors, autoimmune encephalitis), and medication-induced mania (corticosteroids, stimulants) (multiple guideline sources; CANMAT/ISBD 2018). First-onset manic symptoms in adults over 65 are a particular red flag suggesting an organic or neurological etiology rather than classical bipolar I disorder, warranting neuroimaging and specialized laboratory evaluation before committing the patient to lifelong mood stabilizer therapy (CANMAT/ISBD 2018; multiple geriatric psychiatry references).

A significant proportion of first-episode mania emerges in the context of antidepressant treatment for presumed unipolar depression. The DSM-5 stipulates that a full manic episode emerging during antidepressant treatment, but persisting at fully syndromal level beyond the expected effect of that treatment, establishes a bipolar I diagnosis (DSM-5; Stoll et al., 1994, American Journal of Psychiatry). The immediate action for any first presentation is the same regardless of suspected etiology: discontinue antidepressants and stimulants immediately, as continued exposure worsens severity, increases mixed feature risk, and promotes rapid cycling (CANMAT/ISBD 2018; Vieta et al., 2002, Journal of Clinical Psychiatry). Switch risk appears highest with SNRIs and tricyclics compared to SSRIs or bupropion.

For first-episode patients who are medication-naive, atypical antipsychotics (quetiapine, risperidone, aripiprazole) are often the practical initial choice because of their rapid onset, particularly when behavioral control is urgent and the clinician has no prior treatment response data to guide mood stabilizer selection. Psychiatric consultation should be arranged, but in many settings, particularly rural and underserved communities, psychiatric evaluation may involve a wait of weeks to months. In these circumstances, the evidence supports PCPs and advanced practice providers initiating antimanic treatment as a bridging strategy using the agents and dosing described in this module, rather than leaving the patient untreated while waiting for specialist access. The key actions a non-psychiatrist can take immediately are: stop antidepressants, start an atypical antipsychotic at the doses described in Section 5.3, and arrange specialty follow-up as soon as available.

Relapse in known bipolar disorder requires a forensic review before adding new medications. Was the relapse driven by medication non-adherence? Covert substance use? Sub-therapeutic drug levels? Circadian rhythm disruption (shift work, transmeridian travel)? The first mandatory step is obtaining serum levels (lithium, valproate, or carbamazepine) to assess adherence and pharmacokinetic adequacy. Optimizing the current regimen before adding new agents prevents unnecessary polypharmacy (CANMAT/ISBD 2018).

If the patient is already on a therapeutic dose of a first-line agent but remains acutely manic, the algorithm directs adding a second agent with a complementary mechanism (typically adding an antipsychotic to a mood stabilizer, or vice versa). Historical treatment response data should guide selection: for a patient with predominantly depressive polarity, selecting an agent with bipolar depression evidence (quetiapine, cariprazine) during the manic episode is strategically superior to choosing one with pure antimanic properties but weak depression prophylaxis.

6.2 The Severity-Based Algorithm

Mild hypomania (YMRS roughly 12 to 20, no psychotic features, no imminent risk). Monotherapy with a first-line agent is standard. The choice between a mood stabilizer and an antipsychotic depends on the clinical context: if the patient needs rapid behavioral control, an antipsychotic's faster onset (hours to days) favors it over lithium or valproate. If the presentation is mild and the clinician is planning for long-term management, initiating lithium may be preferable because it provides the strongest maintenance platform, including the anti-suicidal benefit (CANMAT/ISBD 2018; APA Practice Guideline).

Moderate to severe mania (YMRS above 20 to 25, significant agitation, functional impairment, or psychotic features). Combination therapy: mood stabilizer (lithium or divalproex) plus an atypical antipsychotic. This is not polypharmacy; it is the evidence-based standard of care. The atypical antipsychotic provides rapid behavioral control and D2 blockade for psychotic features; the mood stabilizer initiates the intracellular changes that build the foundation for long-term stability. CANMAT first-line combinations: lithium or divalproex plus quetiapine, aripiprazole, risperidone, or asenapine (CANMAT/ISBD 2018; Tajika et al., 2022).

For psychotic mania specifically, the antipsychotic component is essential and should not be omitted. A patient with mood-congruent or mood-incongruent delusions or hallucinations during a manic episode requires D2 blockade to resolve the psychotic features.

Treatment-resistant acute mania. If a patient fails to respond to an optimized first-line combination after 10 to 14 days at maximum tolerated doses, the algorithm recommends substituting the antipsychotic component for a different agent with a different receptor profile (CANMAT/ISBD 2018). Clozapine may be considered for highly refractory cases, though its evidence in bipolar mania is limited and its side effect burden is considerable.

6.3 Pediatric and Geriatric Algorithm Modifications

The severity-based algorithm requires significant adaptation at the extremes of the age spectrum.

Pediatric and adolescent mania. The evidence base for acute mania treatment in youth has expanded substantially. A definitive network meta-analysis by Vita et al. (2024, Journal of the American Academy of Child and Adolescent Psychiatry) compared SGAs and mood stabilizers in 2,844 youths (mean age 11.7 years) with bipolar I manic or mixed episodes (Vita et al., 2024, JAACAP). SGAs broadly outperformed classical mood stabilizers in this demographic. Risperidone showed the strongest effect (SMD -1.18; 95% CI: -0.92 to -1.45), followed by olanzapine (SMD -0.77) and aripiprazole (SMD -0.67). CANMAT recommends lithium, risperidone, aripiprazole, asenapine, and quetiapine as first-line for acute youth mania, while divalproex is relegated to third-line due to comparatively weaker efficacy and tolerability in this age group (Yatham et al., 2018; CANMAT/ISBD 2023 update).

A critical clinical consideration: while olanzapine is highly efficacious in youth, its tolerability is exceptionally poor in this population due to rapid, severe metabolic derangement. Youth are particularly susceptible to antipsychotic-induced weight gain and early-onset type 2 diabetes. Aripiprazole or risperidone are therefore preferred first-line agents in pediatric mania despite olanzapine's slightly larger effect size. Weight-based dosing and careful metabolic monitoring are essential in all pediatric antipsychotic prescribing.

For youth with comorbid ADHD, stimulant medications should be discontinued during acute mania, as they may worsen manic symptoms. Stimulant use in patients with comorbid bipolar disorder and ADHD should only be considered after mood stabilization is achieved and maintained, and always with mood stabilizer coverage in place. This topic is discussed in detail in ADHD Module 6A.

Geriatric mania (age 60+). Treatment of older adults requires intense focus on medical comorbidity, polypharmacy interactions, and enhanced sensitivity to anticholinergic and extrapyramidal effects. CANMAT establishes lithium and divalproex as preferred first-line options for geriatric mania, provided renal and hepatic function are carefully monitored (CANMAT/ISBD 2023 update). Lithium clearance declines with age-related renal changes, necessitating lower doses and more frequent level monitoring. Quetiapine is considered second-line in elderly patients due to significant orthostatic hypotension and sedation, which substantially increase fall risk in this population.

6.4 ECT: The Most Effective Treatment for Refractory and Catatonic Mania

When standard pharmacotherapy is insufficient or too slow, particularly in catatonic mania, malignant catatonia, or delirious mania (excited catatonia) with hyperthermia and physiological collapse, electroconvulsive therapy (ECT) is the most effective acute treatment available (Mukherjee et al., 1994, American Journal of Psychiatry; multiple ECT reviews).

The evidence is striking. Mukherjee, Sackeim, and Schnur (1994) reviewed 50 years of psychiatric literature encompassing 589 manic patients treated with ECT and found that 80% achieved marked clinical improvement or full remission (Mukherjee et al., 1994, American Journal of Psychiatry). This 80% remission rate is particularly notable because many patients referred for ECT have already failed multiple adequate medication trials. It should be noted that the Mukherjee review predates modern ECT refinements (ultra-brief pulse stimulation, improved anesthesia protocols), so contemporary remission rates may differ; however, subsequent studies have generally confirmed high efficacy for mania. ECT is also highly effective for acute mania with psychotic features, mixed features, and mania complicated by pregnancy (where medication options are constrained).

ECT for mania typically involves bitemporal electrode placement with 6 to 12 treatments, administered three times per week. While cognitive side effects (anterograde and retrograde amnesia) are the primary concern, they tend to be less severe with unilateral placement and brief-pulse stimulation protocols (multiple ECT reference sources).

The clinical reality is that ECT remains underutilized for acute mania due to persistent stigma, limited availability, and the perception that it is a "last resort." The evidence supports earlier consideration, particularly for catatonic presentations where delays carry mortality risk.

Clinical Pearl: When to Think About ECT Early

ECT should not be the last thing you consider for acute mania; in specific presentations, it should be the first. Catatonic mania (mutism, posturing, rigidity, or paradoxically, extreme purposeless agitation) is a medical emergency with significant mortality risk from physiological exhaustion, hyperthermia, and cardiovascular collapse. Standard pharmacotherapy may be too slow. A bipolar patient with psychotic mania who is not responding to combination pharmacotherapy by day 10 to 14 deserves an explicit conversation about ECT, not as a failure of treatment, but as the most effective tool for this specific clinical scenario.

6.5 From Acute Treatment to Maintenance: The Continuation Principle

One of the most common prescribing errors at the transition from acute to maintenance treatment is prematurely discontinuing the medication that resolved the acute episode. The continuation principle dictates that the agent that successfully treated the acute episode should be maintained through the initial stabilization period (typically at least 6 months) before considering simplification of the regimen (CANMAT/ISBD 2018; multiple maintenance guidelines).

The 2023 CANMAT update specifically noted that continuing the atypical antipsychotic for the first six months after manic stabilization significantly reduces relapse risk. The question of whether to continue the antipsychotic indefinitely depends on the patient's history: a patient with a single manic episode and no prior relapses may tolerate cautious antipsychotic tapering after 6 to 12 months, while a patient with a history of multiple relapses or severe episodes is better served by continued combination therapy.

When transitioning from acute to maintenance, the clinical question shifts from "what treats mania?" to "what prevents the next episode?" This is where lithium's superior maintenance data and anti-suicidal properties become the central considerations. For many patients, the ideal maintenance regimen includes lithium as the foundation (for its unmatched relapse prevention and mortality reduction), with or without a second agent depending on the clinical picture. This transition is discussed in detail in Module 4.

6.6 Measurement-Based Care: Using the YMRS Systematically

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered tool that quantifies manic symptom severity (Young et al., 1978). Systematic YMRS measurement during acute treatment serves three functions: (1) it objectifies what can otherwise feel like subjective clinical judgment, (2) it creates a documented trajectory that informs medication decisions (is the patient actually improving, or does it just feel that way?), and (3) it provides a threshold framework for treatment adjustments (a patient whose YMRS has not decreased by at least 25% by day 10 to 14 may warrant a medication change).

In practice, YMRS assessment at baseline, day 7, day 14, and day 21 provides the minimum data density to guide acute treatment decisions. Response is conventionally defined as a 50% or greater reduction from baseline; remission is defined as a YMRS score below 12.

6.7 Shared Decision-Making When Capacity Is Impaired

Acute mania creates a unique shared decision-making challenge: the patient whose judgment is most impaired by the illness is the one being asked to consent to treatment. As discussed in Section 1.6, manic patients often retain factual understanding of their diagnosis and treatment options but lack appreciation that the diagnosis applies to them.

The evidence-based approach involves three components (multiple SDM and capacity references):

First, treat rapidly to restore capacity. Fast-acting antipsychotics can improve insight within days, opening a window for genuine shared decision-making about the long-term regimen.

Second, involve the support system. Family members and partners can provide critical collateral history (identifying prodromal symptoms the patient did not recognize) and participate in treatment planning, particularly regarding advance directives for future episodes.

Third, when capacity returns, make a prospective plan. The most effective time to develop a crisis plan is during euthymia, not during an episode. This plan should include: what early warning signs look like for this specific patient, what medications were most effective, what the patient authorizes if they lose capacity again, and who the patient designates to make decisions on their behalf.

**In plain language for families: **When someone is in the middle of a manic episode, they often genuinely cannot recognize that they are ill. They may understand what bipolar disorder is and how medication works, but they cannot connect that information to themselves, because the mania tells them that what they are feeling is insight, not illness. This is not stubbornness or denial; it is a symptom of the episode itself. As treatment takes effect, usually within days to a week, this awareness typically returns. The most important planning happens after the episode resolves, when the person can work with their treatment team to create a specific crisis plan for future episodes, while they have the clear thinking to participate fully.

PsychHQ

Acute Mania Prescribing Algorithm & ECT